Hospital
Presentation Medical Center
Presentation Medical Center was paid $8.84M by Medicaid between Jan 2018 and Dec 2024, across 53 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoPRESENTATION MEDICAL CENTER
ROLLA, ND 58367
ROLLA, ND 58367
33aNPI1265404958assigned 02/06/2006
33bProvider typeCritical Access Hospital
28Total paid$8.84M
24GClaims67,187
24DCodes billed53
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in North Dakota
Rank by total paid#1 of 23
Median peer was paid$17K
This provider vs. median522×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,934 | $1.07M | |
| 2019 | 8,965 | $1.25M | |
| 2020 | 7,155 | $1.19M | |
| 2021 | 8,901 | $1.46M | |
| 2022 | 10,238 | $1.31M | |
| 2023 | 11,160 | $1.38M | |
| 2024incomplete | 8,834 | $1.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 9,620 | 6,387 | $2.98M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 11,346 | 8,114 | $2.48M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 27% | 15,655 | 9,900 | $2.38M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.5% | 2,464 | 2,034 | $223K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.2% | 239 | 162 | $190K |
| 80053 | Comprehensive metabolic panel | <1% | 2,379 | 2,088 | $60K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,661 | 3,140 | $53K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 707 | 657 | $40K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,757 | 7,347 | $38K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,748 | 1,681 | $34K |
| 87428 | <1% | 555 | 533 | $32K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 282 | 268 | $30K |
41 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 446 | $30K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 247 | $29K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 76 | $26K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 230 | $24K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 109 | $24K |
| 80050 | General health panel | <1% | 406 | $20K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 718 | $19K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 214 | $17K |
| 87070 | <1% | 1,290 | $15K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 214 | $12K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 73 | $8K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 186 | $8K |
| 81015 | <1% | 1,870 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 37 | $6K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 340 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 445 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 648 | $3K |
| 87807 | <1% | 144 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 43 | $3K |
| 81003 | <1% | 767 | $2K | |
| 81001 | <1% | 240 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 150 | $2K |
| 84484 | <1% | 93 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 43 | $2K |
| 87186 | <1% | 121 | $2K | |
| 81025 | <1% | 114 | $1K | |
| 80061 | Lipid panel | <1% | 46 | $1K |
| 74019 | <1% | 12 | $953.80 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 78 | $921.28 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 57 | $730.34 |
| 87088 | <1% | 55 | $639.33 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13 | $626.40 |
| 90686 | <1% | 92 | $545.27 | |
| 83690 | <1% | 46 | $367.52 | |
| 86140 | <1% | 29 | $235.24 | |
| 90662 | <1% | 13 | $230.40 | |
| 85610 | <1% | 13 | $168.73 | |
| 83605 | <1% | 16 | $71.75 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13 | $12.57 |
| A9270 | Non-covered item or service | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILKIE, PAULA (CEO)
| Provider | Location | Paid |
|---|---|---|
| Presentation Medical Center | Rolla, ND | $1.66M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.